Big deals confirm renewed interest in radiopharmaceuticals
By 
Anthony King2024-02-27T15:53:00
Acquisitions of RayzeBio and Point Biopharma highlight the potential of targeting radioactivity directly to tumour cells
Two billion-dollar acquisitions in late December 2023 confirmed renewed interest in radiopharmaceuticals from big pharma companies. The deals highlight the potential for growth in this class of targeted cancer therapeutics